290 related articles for article (PubMed ID: 17074404)
1. Optimal purification method for Herpes-based viral vectors that confers minimal cytotoxicity for systemic route of vector administration.
Sia KC; Wang GY; Ho IA; Khor HY; Miao L; Hui KM; Lam PY
J Virol Methods; 2007 Feb; 139(2):166-74. PubMed ID: 17074404
[TBL] [Abstract][Full Text] [Related]
2. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome.
Saeki Y; Fraefel C; Ichikawa T; Breakefield XO; Chiocca EA
Mol Ther; 2001 Apr; 3(4):591-601. PubMed ID: 11319922
[TBL] [Abstract][Full Text] [Related]
3. Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas.
Pechan PA; Herrlinger U; Aghi M; Jacobs A; Breakefield XO
J Gene Med; 1999; 1(3):176-85. PubMed ID: 10738566
[TBL] [Abstract][Full Text] [Related]
4. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
5. Increased transcomplementation properties of plasmids carrying HSV-1 origin of replication and packaging signals.
Berthomme H; Fournel S; Epstein AL
Virology; 1996 Feb; 216(2):437-43. PubMed ID: 8607275
[TBL] [Abstract][Full Text] [Related]
6. Herpes simplex virus type-1 amplicon vectors for vaccine generation in acute lymphoblastic leukemia.
Zibert A; Thomassen A; Müller L; Nguyen L; Glouchkova L; Fraefel C; Roskrow M; Meisel R; Dilloo D
Gene Ther; 2005 Dec; 12(23):1707-17. PubMed ID: 16034459
[TBL] [Abstract][Full Text] [Related]
7. Establishment of a novel foreign gene delivery system combining an HSV amplicon with an attenuated replication-competent virus, HSV-1 HF10.
Zhang L; Daikoku T; Ohtake K; Ohtsuka J; Nawa A; Kudoh A; Iwahori S; Isomura H; Nishiyama Y; Tsurumi T
J Virol Methods; 2006 Nov; 137(2):177-83. PubMed ID: 16854473
[TBL] [Abstract][Full Text] [Related]
8. Generation of stable retrovirus packaging cell lines after transduction with herpes simplex virus hybrid amplicon vectors.
Sena-Esteves M; Hampl JA; Camp SM; Breakefield XO
J Gene Med; 2002; 4(3):229-39. PubMed ID: 12112640
[TBL] [Abstract][Full Text] [Related]
9. Gene transfer into hepatocytes mediated by herpes simplex virus-Epstein-Barr virus hybrid amplicons.
Müller L; Saydam O; Saeki Y; Heid I; Fraefel C
J Virol Methods; 2005 Jan; 123(1):65-72. PubMed ID: 15582700
[TBL] [Abstract][Full Text] [Related]
10. Modest increases in the titers of helper virus-free herpes simplex virus 1 (HSV-1) vectors by packaging in a cell line with inducible expression of HSV-1 VP16 or by treatment with N,N'-hexamethylene-bis-acetamide.
Sun M; Lee J; Yu L; Geller AI
Acta Virol; 2000 Dec; 44(6):365-9. PubMed ID: 11332280
[TBL] [Abstract][Full Text] [Related]
11. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity.
Toda M; Martuza RL; Kojima H; Rabkin SD
J Immunol; 1998 May; 160(9):4457-64. PubMed ID: 9574551
[TBL] [Abstract][Full Text] [Related]
12. A novel 'piggyback' packaging system for herpes simplex virus amplicon vectors.
Pechan PA; Fotaki M; Thompson RL; Dunn R; Chase M; Chiocca EA; Breakefield XO
Hum Gene Ther; 1996 Oct; 7(16):2003-13. PubMed ID: 8930661
[TBL] [Abstract][Full Text] [Related]
13. Targeting human glioma cells using HSV-1 amplicon peptide display vector.
Ho IA; Miao L; Sia KC; Wang GY; Hui KM; Lam PY
Gene Ther; 2010 Feb; 17(2):250-60. PubMed ID: 19812609
[TBL] [Abstract][Full Text] [Related]
14. [Expression of foreign genes in adult rats' central nervous system by use of defective herpes simplex virus type 1 vectors].
Yang T; Wang X; Yan Z; Hou Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Dec; 11(4):306-10. PubMed ID: 15617234
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
Kohno SI; Luo C; Nawa A; Fujimoto Y; Watanabe D; Goshima F; Tsurumi T; Nishiyama Y
Cancer Gene Ther; 2007 Nov; 14(11):918-26. PubMed ID: 17693992
[TBL] [Abstract][Full Text] [Related]
16. Efficient and non-toxic gene transfer to cardiomyocytes using novel generation amplicon vectors derived from HSV-1.
Ferrera R; Cuchet D; Zaupa C; Revol-Guyot V; Ovize M; Epstein AL
J Mol Cell Cardiol; 2005 Jan; 38(1):219-23. PubMed ID: 15623439
[TBL] [Abstract][Full Text] [Related]
17. HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells.
Johnston KM; Jacoby D; Pechan PA; Fraefel C; Borghesani P; Schuback D; Dunn RJ; Smith FI; Breakefield XO
Hum Gene Ther; 1997 Feb; 8(3):359-70. PubMed ID: 9048203
[TBL] [Abstract][Full Text] [Related]
18. A novel approach for herpes simplex virus type 1 amplicon vector production, using the Cre-loxP recombination system to remove helper virus.
Logvinoff C; Epstein AL
Hum Gene Ther; 2001 Jan; 12(2):161-7. PubMed ID: 11177553
[TBL] [Abstract][Full Text] [Related]
19. HSV-1 amplicon vectors that direct the in situ production of foot-and-mouth disease virus antigens in mammalian cells can be used for genetic immunization.
D'Antuono A; Laimbacher AS; La Torre J; Tribulatti V; Romanutti C; Zamorano P; Quattrocchi V; Schraner EM; Ackermann M; Fraefel C; Mattion N
Vaccine; 2010 Oct; 28(46):7363-72. PubMed ID: 20851082
[TBL] [Abstract][Full Text] [Related]
20. Helper virus-free herpes simplex virus-1 plasmid vectors for gene therapy of Parkinson's disease and other neurological disorders.
Geller AI; Yu L; Wang Y; Fraefel C
Exp Neurol; 1997 Mar; 144(1):98-102. PubMed ID: 9126158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
